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Abstract
AIM
To investigate possible effects of IRF5 polymorphisms 
in the 3’ UTR region of the IFR5 locus on susceptibility 
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to hepatitis B virus (HBV) infection and progression of 
liver diseases among clinically classified Vietnamese 
patients.
METHODS
Four IFR5  SNPs (rs13242262A/T, rs77416878C/T, 
rs10488630A/G, and rs2280714T/C) were genotyped 
in clinically classified HBV patients [chronic hepatitis 
B (CHB). n  = 99; liver cirrhosis (LC), n  = 131; 
hepatocellular carcinoma (HCC), n  = 149] and in 242 
healthy controls by direct sequencing and TaqMan real-
time PCR assays. 
RESULTS
Comparing patients and controls, no significant asso-
ciation was observed for the four IFR5  variants. 
However, the alleles rs13242262T  and rs10488630G 
contributed to an increased risk of liver cirrhosis (LC 
vs  CHB: OR = 1.5, 95%CI: 1.1-2.3, adjusted P  = 
0.04; LC vs  CHB: OR = 1.7, 95%CI: 1.1-2.6, adjusted 
P  = 0.019). Haplotype IRF5*TCGT  constructed from 
4 SNPs was observed frequently in LC compared to 
CHB patients (OR = 2.1, 95%CI: 1.2-3.3, adjusted P  = 
0.008). Haplotype IRF5*TCAT  occurred rather among 
CHB patients than in the other HBV patient groups (LC 
vs  CHB: OR = 0.4, 95%CI: 0.2-0.8, adjusted P  = 0.03; 
HCC vs  CHB: OR = 0.3, 95%CI: 0.15-0.7, adjusted P  = 
0.003). The IRF5*TCAT haplotype was also associated 
with increased levels of ALT, AST and bilirubin. 
CONCLUSION
Our study shows that IFR5 variants may contribute as a 
host factor in determining the pathogenesis in chronic 
HBV infections.
Key words: Hepatitis B virus infection; Liver diseases; 
IRF5; IFR5 polymorphisms; IFR5 haplotypes
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Core tip: IFR5  is expressed in immune cells and 
mediates Toll-like receptor signal transduction, playing 
a vital role in the induction of antiviral and inflammatory 
response. So far, multiple IFR5  single nucleotide 
polymorphisms have been shown to be associated 
with autoimmune diseases. This study investigated 
the effects of four IFR5  variants on susceptibility to 
hepatitis B virus (HBV) infection and liver disease 
outcomes in HBV infected patients. Two IFR5  variants 
(rs13242262, rs10488630) and constructed haplotypes 
(TCGT , TCAT) were associated with clinical outcomes 
suggesting that IFR5  variants may contribute to 
determine the pathogenesis of HBV infection.
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INTRODUCTION
Hepatitis B virus (HBV) infection is a major health 
concern affecting approximately two billion individuals 
worldwide. 350 million people are chronically infected, 
putting them at risk to develop liver cirrhosis (LC) 
and hepatocellular carcinoma (HCC)[1]. The clinical 
outcome of HBV infection is heterogeneous and a 
consequence of the complex interaction between viral 
and host factors. The host´s genetic background is 
crucial for the outcome of the disease. Evidence for 
a host genetic effects are based on a twin study[2] 
and genome wide association studies (GWASs)[3-5]. 
GWASs examine possible associations of large number 
of genetic variants across the entire human genome, 
taking into account distinct disease phenotypes of 
HBV infection[6]. Many important candidate genes 
have been shown to be significantly associated with 
susceptibility to HBV infection and the progression of 
HBV-related liver diseases[6-8]. 
HBV is a noncytopathic virus as observed in a 
number of asymptomatic HBV carriers who have minimal 
hepatocellular injury and liver necroinflammation 
despite high levels of HBV replication[9]. Thus, hepa-
tocellular injury is strongly dependent on the host 
immune responses[10]. Induction of type I interferons 
(IFNs) by viruses is crucial for innate immunity, which 
is primarily controlled by several transcriptional factors, 
in particular by interferon regulatory factors (IRFs)[11]. 
The IRF family comprises of nine members (IRF1 to 
IRF9), which are characterized by two major domains, 
a highly conserved amino (N)-terminal DNA binding 
domain and a C-terminal IFR association domain 
(IAD)[12]. These regions are important in mediating the 
interaction with transcription co-activators[13]. IRF5, a 
member of the IRF family, is expressed in B cells and 
innate immune cells and mediates Toll-like receptor 
signal transduction, leading to production of several 
inflammatory cytokines such as interleukin 12 and 
IFN-α[14-16]. Therefore, IRF5 plays a vital role in the 
induction of antiviral and inflammatory response [17,18]. 
So far, multiple IRF5 single nucleotide polymorphisms 
(SNPs) have been shown to be associated with 
autoimmune diseases, including systemic lupus ery-
thematosus and rheumatoid arthritis[19,20]. However, 
there are so far no data available on associations of 
IRF5 variants with susceptibility to HBV infection and 
the clinical course of HBV-related liver diseases. This 
study aims to investigate possible effects of IRF5 
polymorphisms on susceptibility to HBV infection and 




379 unrelated Vietnamese HBV-infected patients were 
randomly recruited in a case-control design at the 108 
Military Central Hospital and the 103 Military Hospital of 
the Vietnam Military Medical University, Hanoi, Vietnam. 
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Patients were assigned to subgroups of disease 
based on clinical manifestations and liver function 
tests. Subgroups included chronic hepatitis (CHB, n 
= 99), liver cirrhosis (LC, n = 131) and hepatocellular 
carcinoma (HCC, n = 149). The diagnostic criteria 
have previously been described[21]. Based on clinical 
manifestations and laboratory parameters, patients 
were assigned to the different clinical subgroups as 
previously described. Briefly, the CHB patients were 
characterized based upon clinical syndromes such 
as fatigue, anorexia, jaundice, hepatomegaly, hard 
density of the liver, splenomegaly, hyperbilirubinemia, 
elevated levels of AST and ALT, HBsAg positive for 
longer than 6 mo. The HBV-related LC patients were 
characterized as patients infected with HBV (HBsAg 
positive) showing the clinical manifestations such as 
anorexia, nausea, vomiting, malaise, weight loss, 
abdominal distress, jaundice, edema, cutaneous arterial 
‘‘Spider’’ angiomas, palma erythema, ascites, shrunken 
liver, splenomegaly, hyperbilirubinemia, elevated 
levels of AST and ALT, prolonged serum prothrombin 
time, and decreased serum albumin. The HBV-related 
hepatocellular carcinoma patients were characterized as 
patients infected with chronically HBV (HBsAg positive), 
abdominal pain, an abdominal mass in the right upper 
quadrant, blood-tinged ascites, weight loss, anorexia, 
fatigue, jaundice, prolonged serum prothrombin 
time, hyperbilirubinemia, elevated levels of AST, ALT 
and serum a-fetoprotein (AFP), ultrasound showed 
tumor, liver biopsy and histopathology showing tumor 
cells. None of the patients were under any antivirals 
during sampling. None of the patients had a history of 
alcohol or drug abuse. All participants were confirmed 
to be negative for anti-HCV and anti-HIV antibodies 
by ELISA assays. Liver function tests including the 
assessment of alanine transaminase (ALT), aspartate 
transaminase (AST), total bilirubin and direct bilirubin, 
albumin and prothrombin levels were performed using 
an autoanalyser (AU640 Chemistry Analyzer, Beckman 
Coulter, CA, United States). 242 blood samples from 
healthy individuals (HC) were collected from blood 
banks as the control group. All 242 control individuals 
were negative for HBsAg, anti-HCV and anti-HIV 
antibodies. All specimens were frozen at -20 ℃ until 
use. 
IRF5 SNP selection
The four IRF5 SNPs rs13242262A/T, rs77416878C/T, 
rs10488630A/G, and rs2280714G/A located closely 
at the 3′ downstream regions of the IRF5 locus were 
selected for this study. Two SNPs (rs13242262, and 
rs2280714) have been shown to be associated with 
IRF5 mRNA expression and activation of the interferon 
α pathway in different world populations[22]. 
IRF5 variant genotyping 
Genomic DNA was isolated from 200 μL of whole blood 
using a DNA purification kit (Qiagen, Hilden, Germany). 
The fragments containing the SNPs rs13242262A/T 
and rs77416878C/T were amplified by PCR using the 
primer pairs IRF5-F1: 5’-AGG CCT GTG CAG TTC TAC 
TCC C-3’ and IRF5-R1: 5’-CCT CAC ACT GGC CTG CCT 
TTA C-3’. PCR amplifications were carried out in 25 
μL reaction volumes containing: 1 x PCR buffer, 0.2 
mmol/L dNTPs, 1 mmol/L MgCl2, 0.15 mmol/L of each 
primer, 1 unit of Taq polymerase and 50 ng of genomic 
DNA. Cycling conditions: denaturation at 95 ℃ for 5 
min, followed by 35 cycles of three-step cycling with 
denaturation at 94 ℃ for 40 s, annealing at 61 ℃ 
for 40 s, and extension at 72 ℃ for 45 s and a final 
extension at 72 ℃ for 7 min. 
PCR products were purified using the Exo-SAP-IT 
PCR Product Cleanup Reagent (Affymetrix Santa Clara, 
mmol/L) 5 μL of purified PCR products were used 
as templates. Sequencing was performed using the 
BigDye terminator v.1.1 cycle sequencing kit (Applied 
Biosystems, Foster City, CA, United States) on an ABI 
3130XL DNA sequencer according to the manufacturer’
s instructions. The polymorphisms were identified by 
assembling DNA sequences with the reference sequence 
of the IFR5 gene obtained from the NCBI database 
(GenBank accession number: NC-00007). In addition, 
the two SNPs rs10488630A/G, and rs2280714G/A were 
genotyped using TaqMan® SNP genotyping assays 
according to the instruction of the manufacturer.
Statistical analysis
The data were analyzed using R version 3.1.2 (http://
www.r-project.org). Permutation tests were used to 
compare groups for quantitative variables permuted for 
1000 iterations. Genotype and haplotype frequencies 
were analyzed by gene counting and expectation-
maximum (EM) algorithms and the significance of 
deviation from Hardy-Weinberg equilibrium was 
tested using the random-permutation procedure 
as implemented in the Arlequin v. 3.5.1.2 software 
(http://lgb.unige.ch/arlequin). We used a binary logistic 
regression model adjusted for age and gender to analyze 
associations of IRF5 variants and haplotypes with HBV-
related liver diseases. The false discovery rate correction 
method was used for multiple comparisons[23] and 
adjusted P values are given. The level of significance 
was set at a value of P < 0.05 and all reported P values 
are two-sided.
RESULTS
Baseline characteristics of study participants
The baseline characteristics of the 379 HBV-infected 
patients from the different subgroups with well-
characterized clinical profiles and from the 242 healthy 
controls are described in Table 1. Most patients and 
controls were male (81% and 64%). The median 
age of patients increased according to progression 
of liver disease; healthy controls were younger than 
the patients. The levels of ALT, AST and bilirubin were 
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SNPs did not differ between HBV patients or subgroups 
and controls, indicating that IRF5 SNPs are not 
associated with HBV infection per se. Among chronic 
HBV carriers, rs13242262TT and rs10488630GG 
genotype were significantly more frequent among LC 
patients compared to CHB patients (rs13242262TT: 
OR = 3.1, 95%CI: 1.2-7.8, adjusted P = 0.014; 
rs10488630GG, OR = 3.0, 95%CI: 1.0-9.5, adjusted 
P = 0.045, Table 2). A similar trend was observed for 
rs13242262T (OR = 1.5, 95%CI: 1.1-2.3, adjusted P 
= 0.04) and rs10488630G (OR = 1.7, 95%CI: 1.1-2.6, 
adjusted P = 0.019; Table 2). For SNPs rs77416878C/
T, and rs2280714T/C all comparisons between patient 
subgroups using binary logistic model adjusted for 
age and gender did not indicate any significant 
difference (Table 3). These results show that, of the 
four SNPs genotyped, the two variants rs13242262 
and rs10488630 are associated with liver disease pro-
gression.
Association of IRF5 haplotypes with HBV-infected liver 
diseases
Haplotypes were constructed based on the four SNPs. 
Among nine IRF5 haplotypes detected, the five common 
significantly higher in patients with CHB compared to 
the other subgroups (P < 0.0001). As expected, the 
albumin and prothrombin levels as well as platelet 
counts were significantly lower in patients with LC 
compared to patients without LC (P < 0.001). Alpha-
fetoprotein (AFP) levels were higher in HCC patients 
with or without LC compared to CHB and LC groups 
(P < 0.0001). Viral loads did not differ significantly 
between HBV virus subgroups (P > 0.05). 
Association IRF5 variants with HBV-related liver 
diseases
The genotype frequencies of the four IRF5 variants 
rs13242262A/T, rs10488630A/G, rs77416878C/T, 
rs2280714T/C in HBV patients and in HCs were in Hardy-
Weinberg equilibrium (P > 0.05). Linkage disequilibrium 
analysis revealed strong allelic combinations between 
rs13242262 and rs2280714; rs13242262 and 
rs10488630; rs10488630 and rs2280714 for both HBV 
infected patients and HCs (Figure 1). Genotype and 
allele frequencies of the IRF5 SNPs in patients and HCs 
as well as the comparisons between different subgroups 
are given in Tables 2 and 3. 
Genotype and allele frequencies of the four IRF5 
Table 1  Clinical profiles of 242 healthy individuals and 379 hepatitis B virus-infected patients 
Characteristics HC (n  = 242) CHB (n  = 99) LC (n  = 131) HCC (n  = 149) P  values
Age (yr) 39 (18-79) 41 (19-78) 52 (17-78) 53 (18-79) < 0.0001
Gender (Male/Female) 156/86 82/17 105/26 119/30 < 0.0001
AST (IU/L) NR   219 (17-3732)    74 (12-720)  59 (16-513) < 0.0001
ALT (IU/L) NR   158 (12-4593)     59 (9-1354)  47 (13-471) < 0.0001
Total bilirubin (µmol/L) NR      46.6 (1.8-795)      31 (1.2-722) 17 (2-290) < 0.0001
Direct bilirubin (µmol/L) NR    29.9 (1-512)  17 (1-450)         7.1 (1.2-189) < 0.0001
Albumin (g/L) NR 42 (23-48)   30 (20-47) 39 (27-49) < 0.0001
Prothrombin (% of standard) NR   85 (50-120)      47.5 (15-101)    80 (31-115) < 0.0001
HBV-DNA (copies/mL) NA 1.8 × 105 (4 × 102-8.1 × 106) 8.3 × 104 (2 × 102-4.1 × 106) 9.4 × 104 (2.9 × 102-1.0 × 105) NS
Alfa Feto Protein (IU/L) NR         4.3 (1.5-300) 8.6 (1.2-400) 196 (1.1- 438) < 0.0001
CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma; PLT: Platelets; AST and ALT: Aspartate and alanine amino transferase; IU: 
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Figure 1  IRF5 linkage disequilibrium maps. Pairwise r2 between 4 polymorphisms in the IRF5 locus in the 3’ UTR region in Vietnamese hepatitis B virus infected 
patients (A) and in healthy controls (B) are presented. The color scale from white to dark indicates r2 values from 0 to 1. The blocks of grey and dark grey represent 
SNPs that are all in high linkage disequilibrium with each other.
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haplotypes rs13242262/rs77416878/rs10488630/
rs2280714 ACAC, TCGT, TCAT, ACAT, and TTAT 
were observed in both HCs and HBV patients. Their 
frequencies are summarized in Table 4. We compared 
the haplotype frequencies between HCs and all HBV 
patients as well as the disease subgroups (HC vs all 
HBV; HC vs LC; HC vs CHB; HC vs HCC). The results did 
not indicate any significant difference (data not shown).
We further compared haplotype frequencies between 
the HBV subgroups. Haplotype TCGT was found more 
frequently among LC compared to CHB patients (LC 
vs CHB: OR = 2.1, 95%CI: 1.2-3.3, adjusted P = 
0.008), indicating that this haplotype may contribute 
significantly to an increased risk of LC in HBV carriers. 
However, a contradictory finding was observed for the 
haplotype TCAT, which was observed significantly more 
frequent in CHB compared to LC and HCC patients (LC 
vs CHB: OR = 0.4, 95%CI: 0.2-0.8, adjusted P = 0.037 
and HCC vs CHB: OR = 0.3, 95%CI: 0.15-0.7, adjusted 
P = 0.003). This haplotype appears to partly protect 
from the risk of the advanced clinical manifestations 
LC and HCC in chronic HBV carriers. There were no 
differences in comparisons of the TCGT and TCAT 
haplotype frequencies between LC and HCC patients. 
Also, no significant difference was observed when 
frequencies of other haplotypes were compared (Table 
4). 
Association of IRF5 polymorphisms and haplotypes 
with clinical parameters
To explore the possible impact of the four SNPs on 
disease outcomes, the SNP frequencies were correlated 
with several liver function tests, a cancer marker, and 
viral loads. No significant associations of IRF5 genotypes 
with the parameters ALT, AST, total and direct bilirubin, 
prothrombin, AFP and HBV-DNA loads were observed 
(adjusted P > 0.05). 
We further examined the association of five common 
IRF5 haplotypes with clinical outcomes of HBV infection. 
Patients with haplotype TCAT had higher levels of AST, 
ALT, total bilirubin and direct bilirubin compared to the 
other haplotypes (Figure 2). No significant differences 
of viral loads, prothrombin and AFP levels among five 
common haplotypes were observed.
DISCUSSION
IRF5 is a particularly interesting member of the 
IRF family, which are crucial in the innate immune 
response with a variety of activities like activation 
of type I IFN genes, inflammatory cytokines and 
tumor suppressors[24,25]. Therefore, IRF5 is involved 
in many conditions, including autoimmune diseases, 
viral infections and cancers[11,19,20]. In this study, 
we studied the role of IRF5 polymorphisms in HBV 
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Figure 2  Association of IRF5 haplotypes with clinical parameters in hepatitis B virus patients. Box-plots illustrate median values with 25 and 75 percentiles 
with whiskers to 10 and 90 percentiles; the distribution of IRF5 haplotypes to liver enzymes, bilirubin and hepatitis B virus viral load was executed using pairwise 
permutation tests. Adjusted P values are presented under the false discovery rate correction method applied for multiple comparisons. NS: Not significant; AST and 
ALT: Aspartate and alanine amino transferase.
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P < 0.05 P < 0.05
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infected patients. IRF5 variants are associated with LC 
progression in patients with CHB while the constructed 
haplotypes are associated with LC and HCC progression 
in CHB patients. In addition, IRF5 variants and their 
constructed haplotypes are associated with clinical 
outcomes of HBV infection. For the first time we provide 
evidence of the functional role of IRF5 in immune 
response to the clinical outcome of HBV infection.
Host immune factors are crucial to the pathogenesis 
of HBV infection through genetic and epigenetic 
modifications and via the effects of cytokines[26]. 
Interferons are produced by the host in response to 
certain viral infections in order to inhibit viral replication. 
Induction of IFN is required for the defense against 
hepatitis viruses and further progression of related 
liver disease[27]. IRF5 is a transcriptional factor that 
can induce type I interferons and, therefore, appears 
to play an important role in the clinical course of HBV 
infection. To the best of our knowledge, this study is the 
first exploratory investigation of IRF5 polymorphisms 
addressing the clinical outcome of HBV-related liver 
diseases. Among four SNPs studied here, rs13242262A/
T and rs10488630A/G appeared were with liver 
cirrhosis. In addition, the IRF5 haplotypes TCGT and 
TCAT are associated with liver cirrhosis in patients 
with chronic hepatitis B. SNP rs10488631 located in 
the same region was identified to be associated with 
primary biliary cirrhosis in populations of European 
descent[28]. However, this SNP was homogeneous 
in Asian populations and therefore excluded from 
analyses in this study. In addition, SNPs rs3807306 
Table 2  Association of IRF5 rs13242262A/T and rs10488630A/G with hepatitis B virus-related liver cirrhosis n  (%)
IRF5 variants HC, n  = 242 CHB, n  = 99 LC, n  = 131 HCC, n  = 149 LC vs  CHB
OR (95%CI) P  value
rs13242262 A/T
   AA   67 (27.7)      27 (27.3)   32 (24.4)   45 (30.2) Reference
   AT 119 (49.2)      59 (59.6)   65 (49.6)   77 (51.7) 1.0 (0.5-2.0) NS
   TT   56 (23.1)      13 (13.1)   34 (26.0)   27 (18.1) 3.1 (1.2-7.8) 0.014
Allele
   A 253 (52.3) 113 (57) 129 (49.2) 165 (55.3) Reference
   T 231 (47.7)   85 (43) 133 (50.8) 133 (44.7) 1.5 (1.1-2.3) 0.040
Dominant 
   AA   67 (27.7)      27 (27.3) 32(24.4)   45 (30.2) Reference
   AT + TT 175 (72.3)      72 (72.7)  99 (75.6) 104 (69.8) 1.3 (0.7-2.6) NS
Recessive
   AA + AT 186 (76.9)   86 (87)  97 (74.0) 122 (81.9) Reference
   TT   56 (23.1)   13 (13)   34 (26.0)   27 (18.1) 2.8 (1.3-5.9) 0.0057
rs10488630 A/G
   AA 115 (47.5)      58 (58.6)   59 (45.1)   73 (49.0) Reference
   AG 104 (43.0)      36 (36.4)   56 (42.7)   63 (42.3) 1.6 (0.9-2.9) 0.100
   GG 23 (9.5)      5 (5.0)   16 (12.2) 13 (8.7) 3.0 (1.0-9.5) 0.045
Allele
   A 334 (69)    152 (76.8) 174 (66.4) 209 (72.3) Reference
   G 150 (31)      46 (23.2)   88 (33.6)   89 (27.7) 1.7 (1.1-2.6) 0.019
Dominant
   AA 115 (47.5)      58 (58.6)   59 (45.0) 73 (49) Reference
   AG + GG 127 (52.5)       41 (41.4)   72 (55.0) 76 (51) 1.8 (1.0-3.2) 0.035
Recessive
   AA + AG 219 (90.5)      94 (94.9) 115 (87.8) 136 (91.3) Reference
   GG 23 (9.5)      5 (5.1)   16 (12.2) 13 (7.8) 2.4 (0.8-7.2) 0.100
HC: Healthy controls; CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma.
Table 3 Al le le and genotype frequencies of IRF5  
rs77416878C/T and rs2280714T/C in Vietnamese patients 
with hepatitis B virus-related liver diseases n  (%)
IRF5 variants HC, 
n  = 242
CHB, 
n  = 99
LC, 
n  = 131
HCC,
n  = 149
rs77416878
   CC 192 (79.4)    79 (79.8)      98 (74.8)    115 (77.2)
   CT   48 (19.8)   19 (19.2)      32 (24.4)      31 (20.8)
   TT   2 (0.8) 1 (1)      1 (0.8)   3 (2)
Allele
   C 432 (89.3) 177 (89.4) 228 (87)    261 (87.6)
   T   52 (10.7)    21 (10.6)   34 (13)      37 (12.4)
Dominant
   CC 192 (79.4)   79 (79.8)      98 (74.8)    115 (77.2)
   CT + TT   50 (20.6)   20 (20.2)       33 (24.4)      34 (22.8)
Recessive
   CC + CT 240 (99.2) 98 (99)    130 (99.2) 146 (98)
   TT   2 (0.8) 1 (1)      1 (0.8)   3 (2)
rs2280714
   TT   84 (34.7)    31 (31.3)      47 (35.9)      39 (26.2)
   TC 114 (47.1)    52 (52.5)      69 (52.7)      87 (58.4)
   CC   44 (18.2)    16 (16.2)      15 (11.4)      23 (15.4)
Allele
   T 282 (58.3) 114 (57.6)    163 (62.2)    165 (55.4)
   C 202 (41.7)   84 (42.4)      99 (37.8)    133 (44.6)
Dominant
     84 (34.7)    31 (31.3)       47 (35.9)      39 (26.2)
   TC + TT 158 (65.3)    78 (68.7)      84 (64.1)     110 (73.8)
Recessive
   TT + TC 198 (81.8)    83 (83.8)     116 (88.6)     126 (84.6)
   CC   44 (18.2)    16 (16.2)       15 (11.4)      23 (15.4)
HC: Healthy controls; CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: 
Hepatocellular carcinoma. All comparisons between groups using binary 
logistic model adjusted for age and gen did not indicate a significant 
difference (adjusted P > 0.05, data not shown in this table).
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and rs4728142 in the IRF5 gene have been implicated 
as susceptibility loci for primary biliary cirrhosis[29]. 
The process of liver cirrhosis in HBV infection is a 
results of the interplay between viral factors and host 
immune responses through activation of inflammatory 
cytokines[30]. A recent study has shown that among 
several IRF5 SNPs, the variants rs13242262, rs2280714 
and rs10488630 in the 3’UTR region are associated 
with increased IRF5 mRNA expression[22]. Studies have 
indicated that a variety of cytokines are dependent on 
IRF5[24,31]. Several IRF5-modulated genes (e.g., ISGs 
and STATs) involved in the type I IFN signaling pathway 
are significantly over-expressed in response to viral 
infection[18]. This supports the findings of our study, 
namely that these SNPs may contribute to progression 
of HBV-related liver diseases through regulating IRF5 
expression and subsequent activation of genes in the 
type I IFN signaling pathway like ISG15 as seen in our 
study[7]. Furthermore, although all four studied SNPs 
were not associated with HCC, the haplotype TCAT 
contributes to a decreased risk of HCC development 
in patients with chronic hepatitis B. Data concerning 
the association between IRF5 and HCC are scarce. 
Nevertheless, methylation of IRF5 has been suggested 
to be associated with HCC in a Korean study[32]. The role 
of IRF5 in the development of HBV-related HCC needs 
to be explored further.
Although SNPs rs77416878C/T and rs2280714T/
C are not associated with HBV-related liver disease 
and no significant association of all four SNPs studied 
with clinical parameters, constructed haplotypes 
are associated with clinical outcomes. Notably, the 
haplotype TCAT was observed significantly more 
frequent in CHB compared to LC and HCC patients, 
suggesting that this haplotype appears to partly protect 
from the risk of the advanced clinical manifestations 
LC and HCC in chronic HBV carriers. However, patients 
with the haplotype TCAT had higher levels of AST, ALT, 
total bilirubin and direct bilirubin compared to the other 
haplotypes. In fact, the clinical outcome or clinical 
progression of liver diseases in HBV infected patients 
are affected by several factors and are considered as 
a result of viral-host interaction. Therefore, we believe 
that haplotype TCAT is an important host factor in HBV 
infection but this haplotype only may not be a host 
factor in determining the overall clinical outcome of 
disease. 
Until now, most studies have identified distinct IRF5 
haplotypes to be associated with high serum IFN-α 
activity and with systemic lupus erythematosus[33-36]. 
In addition, the IRF5 risk haplotype TCC, which 
contains the risk alleles rs13242262, rs10488631 and 
rs2280714 are associated with increased IRF5, IFN-α, 
and IFN-inducible chemokine expression in healthy 
individuals[22]. However, our study did not assess 
the relationship of the IRF5 risk haplotypes ACAC, 
TCAT, TCGT with IRF5 expression, IFN-α activity and 
other related IFN-α gene. This is one of the study’s 
limitations; in fact the function of IRF5 in HBV infection 
needs further investigations. Nevertheless, we 
assume that the IRF5 risk haplotypes may affect the 
expression of multiple downstream genes in the IFN-α 
signaling pathway and certain inflammatory cytokines 
in HBV infection. 
In conclusion, IRF5 variants rs13242262A/T and 
rs10488630A/G are associated with LC progression 
in patients with CHB. IRF5 haplotypes appear to 
influence the outcome of HBV infection. Further studies 
in this direction will provide insights into a role of IRF5 




Hepatitis B virus (HBV) infection is a major health concern in Vietnam. 
Investigations were carried out to determine IRF5 polymorphisms in the 3’ UTR 
region of the IFR5 locus on susceptibility to HBV infection and progression of 
liver diseases among clinically classified Vietnamese patients.
Research motivation
IRF5 is a particularly interesting member of the IRF family, which are crucial in 
the innate immune response with a variety of activities like activation of type 
I IFN genes, inflammatory cytokines and tumor suppressors. There are so far 
no data available on associations of IRF5 variants with susceptibility to HBV 
Table 4  Haplotype distribution among chronic hepatitis B virus carriers and the association of IRF5 haplotypes with hepatitis B 
virus-infected liver diseases n  (%)
Haplotypes HC,
n  = 484
CHB, 
n  = 198
LC, 
n  = 298
HCC, 
n  = 262
LC vs  CHB HCC vs  CHB HCC vs  LC
OR (95% CI) P  value OR (95% CI) P  value OR (95%CI) P  value
ACAC  196 (40.6)   83 (41.9)    98 (37.4)  132 (44.3) Reference Reference Reference
TCGT  141 (29.0)    37 (18.7)    86 (32.7)    81 (27.2) 2.1 (1.2-3.3) 0.008 NS 0.7 (0.4-1.1) 0.08
TCAT  33 (6.8)    27 (13.6)  12 (4.6) 13 (4.4) 0.4 (0.2-0.8) 0.037 0.3 (0.15-0.7) 0.003 NS
ACAT    54 (11.2) 24 (12)    30 (11.5)    31 (10.4) NS NS NS
TTAT    49 (10.2)  18 (9.1) 34 (13)    33 (11.1) NS NS NS
ACGC    2 (0.4)    1 (0.5) 0 (0)    1 (0.3) NS NS NS
ACGT 5 (1)    5 (2.5)     1 (0.4) 3 (1) NS NS NS
TCGC    2 (0.4) 0 (0)    1 (0.4) 0 (0) NS NS NS
TTGT    2 (0.4)    3 (1.5) 0 (0)   4 (1.3) NS NS NS
HCC: Hepatocellular carcinoma. Comparison between HC vs HBV patient group did not indicate any significant difference (data not shown in this table). 
OR and P values were calculated by using binary logistic model adjusted for age and gender, CHB: Chronic hepatitis B; LC: Liver cirrhosis.
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infection and the clinical course of HBV-related liver diseases. 
Research objectives 
This study aims to investigate possible effects of IRF5 polymorphisms on 
susceptibility to HBV infection and progression of liver diseases among clinically 
classified Vietnamese patients.
Research methods
The four IRF5 SNPs rs13242262A/T, rs77416878C/T, rs10488630A/G, and 
rs2280714G/A located closely at the 3′ downstream regions of the IRF5 locus 
were selected for this study. IRF5 variant genotyping was performed by direct 
sanger sequencing and by application of TaqMan® SNP genotyping assays.
Research results
Three hundred seventy-nine unrelated Vietnamese HBV-infected patients were 
randomly recruited in a case-control design. IRF5 variants are associated with 
LC progression in patients with CHB while the constructed haplotypes are 
associated with LC and HCC progression in CHB patients. In addition, IRF5 
variants and their constructed haplotypes are associated with clinical outcomes 
of HBV infection. 
Research conclusions
Host immune factors are crucial to the pathogenesis of HBV infection. For the 
first time the authors provide evidence of the functional role of human IRF5 
in immune response to the clinical outcome of HBV infection. IRF5 variants 
rs13242262A/T and rs10488630A/G are associated with LC progression in 
patients with CHB. IRF5 haplotypes appear to influence the outcome of HBV 
infection.
Research perspectives
Further studies in this direction will provide insights into a role of IRF5 variants 
as prognostic markers of HBV-related liver diseases.
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